芬兰人和拉普人中异喹胍羟基化的多态性。
Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
作者信息
Arvela P, Kirjarinta M, Kirjarinta M, Kärki N, Pelkonen O
机构信息
Department of Pharmacology, University of Oulu, Finland.
出版信息
Br J Clin Pharmacol. 1988 Nov;26(5):601-3. doi: 10.1111/j.1365-2125.1988.tb05301.x.
Abstract
Debrisoquine hydroxylation polymorphism was studied in 155 Finns and 70 Lapps. The frequency of the poor metabolizer phenotype was 3.2% among Finns (95% confidence interval 0.4-6.0%) and 8.6% among Lapps (95% confidence interval 2.0-15.1%).
摘要
对155名芬兰人和70名拉普人进行了异喹胍羟基化多态性研究。在芬兰人中，代谢不良者表型的频率为3.2%（95%置信区间0.4 - 6.0%），在拉普人中为8.6%（95%置信区间2.0 - 15.1%）。
相似文献
1
Polymorphism of debrisoquine hydroxylation among Finns and Lapps.芬兰人和拉普人中异喹胍羟基化的多态性。
Br J Clin Pharmacol. 1988 Nov;26(5):601-3. doi: 10.1111/j.1365-2125.1988.tb05301.x.
2
Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.中国人中异喹胍4-羟化的多态性及慢代谢者的家系研究。
Zhongguo Yao Li Xue Bao. 1990 Jan;11(1):7-10.
3
Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Clin Pharmacol Ther. 1984 Oct;36(4):515-9. doi: 10.1038/clpt.1984.212.
4
Diurnal effects on debrisoquine hydroxylation phenotyping.
Eur J Clin Pharmacol. 1988;35(4):441-2. doi: 10.1007/BF00561381.
5
Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
Hum Toxicol. 1988 May;7(3):273-6. doi: 10.1177/096032718800700308.
6
Debrisoquine hydroxylation phenotyping: do we expect too much?异喹胍羟基化表型分析：我们期望过高了吗？
Lancet. 1990 Sep 15;336(8716):694. doi: 10.1016/0140-6736(90)92193-l.
7
Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.爱沙尼亚人对异喹胍和苯妥英羟化作用的多态性
Pharmacol Toxicol. 1993 Feb;72(2):113-5. doi: 10.1111/j.1600-0773.1993.tb00300.x.
8
Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism.
Lancet. 1984 Dec 15;2(8416):1393. doi: 10.1016/s0140-6736(84)92081-6.
9
Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.加纳人和高加索人中异喹胍羟基化多态性
Clin Pharmacol Ther. 1979 Nov;26(5):584-91. doi: 10.1002/cpt1979265584.
10
Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.在药物研发早期发现去甲丙咪嗪羟化能力差的个体中CGP 15 210 G的药代动力学改变。
Br J Clin Pharmacol. 1985 Jul;20(1):81-4. doi: 10.1111/j.1365-2125.1985.tb02802.x.
引用本文的文献
1
Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.CYP1A1和CYP2D6基因多态性：与肺癌易感性的可能关联。
Environ Health Perspect. 1993 Oct;101 Suppl 3(Suppl 3):109-12. doi: 10.1289/ehp.93101s3109.
2
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.欧洲人群中异喹胍和甲妥英的羟化多态性
Eur J Clin Pharmacol. 1990;39(6):533-7. doi: 10.1007/BF00316090.
3
The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.以安替比林、三甲双酮和异喹胍作为模型底物，研究地尔硫䓬对人体肝脏药物代谢酶的影响。
Br J Clin Pharmacol. 1991 Mar;31(3):353-5. doi: 10.1111/j.1365-2125.1991.tb05543.x.
4
Debrisoquine oxidation polymorphism in a Tasmanian population.塔斯马尼亚人群中的异喹胍氧化多态性。
Eur J Clin Pharmacol. 1991;40(5):529-32. doi: 10.1007/BF00315235.
本文引用的文献
1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
[Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
Schweiz Med Wochenschr. 1982 Jul 24;112(30):1061-7.
3
The Upjohn Award Lecture 1981/La Conférence Upjohn 1981. The metabolism of xenobiotics in different populations.1981年厄普约翰奖讲座/1981年厄普约翰会议。不同人群中异生物素的代谢。
Can J Physiol Pharmacol. 1982 Jan;60(1):1-12. doi: 10.1139/y82-001.
4
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.运用分析双峰分布的新方法对人司巴丁和异喹胍代谢的遗传控制。
J Med Genet. 1983 Oct;20(5):321-9. doi: 10.1136/jmg.20.5.321.
5
The genetic control of drug oxidation in the liver.肝脏中药物氧化的遗传控制。
Int J Clin Pharmacol Res. 1983;3(6):421-5.
6
Demography of the Skolt Lapps in Northern Finland.芬兰北部斯科尔特拉普人的人口统计学
Suom Hammaslaak Toim. 1971;67:Suppl 1:24-38.
7
Isoniazid inactivation in Finns and Lapps as demonstrated by various methods.通过多种方法证明芬兰人和拉普人中异烟肼的失活情况。
Am Rev Respir Dis. 1973 Aug;108(2):375-8. doi: 10.1164/arrd.1973.108.2.375.
8
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.日本人群与白种人群之间在异喹胍和甲妥英羟基化遗传多态性上的种族差异。
Clin Pharmacol Ther. 1985 Oct;38(4):402-8. doi: 10.1038/clpt.1985.194.
9
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.一项关于决定异喹胍多态性羟化的遗传和环境因素的家族研究。
Clin Pharmacol Ther. 1985 Oct;38(4):394-401. doi: 10.1038/clpt.1985.193.
10
Confidence intervals rather than P values: estimation rather than hypothesis testing.置信区间而非P值：估计而非假设检验。
Br Med J (Clin Res Ed). 1986 Mar 15;292(6522):746-50. doi: 10.1136/bmj.292.6522.746.
Zotero 插件